Semaglutide is the most extensively studied compound in the GLP-1 class, and the
human evidence base for it is unusually large. This monograph summarizes the
pharmacology and the trial record.
Chemical identity & structure.
Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist — a synthetic
analog of the human incretin hormone GLP-1. Its structure is engineered for
durability: an amino-acid substitution at position 8 (alpha-aminoisobutyric acid,
"Aib") blocks degradation by the enzyme DPP-4, and a C18 fatty-diacid chain
attached via a linker promotes reversible binding to albumin in the bloodstream.
Together these modifications extend the half-life to roughly 7 days.
Mechanism of action.
Semaglutide activates the GLP-1 receptor. The downstream effects relevant to
metabolic research are: glucose-dependent stimulation of insulin secretion,
suppression of glucagon, slowing of gastric emptying, and central effects on
appetite and satiety signaling via GLP-1 receptors in the hypothalamus and
hindbrain. The "glucose-dependent" qualifier matters — insulin release is
amplified only when glucose is elevated, which is relevant to the class's
hypoglycemia profile.
Key research findings.
In the SUSTAIN program (type 2 diabetes), semaglutide improved glycemic control
and produced weight loss as a secondary outcome. The STEP program studied
semaglutide specifically for weight management at higher doses and documented
substantial sustained weight loss. The SELECT trial reported a
reduction in major adverse cardiovascular events in a population with
established cardiovascular disease and overweight/obesity. The FLOW trial
examined kidney outcomes.
The research / citation base.
Semaglutide is approved by the FDA and other regulators for type 2 diabetes
(Ozempic, Rybelsus) and for chronic weight management (Wegovy). The trial
program (SUSTAIN, PIONEER, STEP, SELECT, FLOW) is large and published in major
peer-reviewed journals. This is one of the best-evidenced compounds in the
entire peptide space.
In the STEP 1 phase 3 trial by Wilding and colleagues (2021), 1961 adults with overweight or obesity without diabetes were randomly assigned to 68 weeks of treatment with once-weekly subcutaneous semaglutide (at a dose of 2.4 mg) or placebo, plus lifestyle intervention (PubMed).
Quality & sourcing notes.
Counterfeit and underdosed semaglutide is a documented, serious problem in the
research-grade supply chain. A credible COA should confirm identity by mass
spectrometry and purity by HPLC, and should be batch-specific. Peptide mass for
semaglutide is approximately 4114 Da — a COA reporting a materially different
mass is a red flag.
*Research-use note: This is an educational summary of published research.
Semaglutide is a prescription drug; this monograph is research context only and
is not medical advice.*
